Fasylpharma SRL
Fasylpharma reported total assets of 250,318 € at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Feb 2026).
The score of Fasylpharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -3 % Total assets -23 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Fasylpharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 15,509 € | ||||
| Equity | 234,342 € | ||||
| Cash | 85,763 € | ||||
| EBITDA | 37,832 € | ||||
| Total assets | 250,318 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 23 Feb 2026
- Year ended 30 Jun 2024filed on 17 Feb 2025
- Year ended 30 Jun 2023filed on 06 Feb 2024
- Year ended 30 Jun 2022filed on 09 Feb 2023
- Year ended 30 Jun 2021filed on 31 Jan 2022
Fasylpharma's financial analysis
- Solvency93.6%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Fasylpharma
Fasylpharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0478.056.184
- VAT number
- BE0478056184
- Peppol
- Registered · 0208:0478056184 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Jul 2002
- Registered office
- 6250 Aiseau-Presles
- Latest accounts
- 2025 · filed on 23 Feb 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Fasylpharma (SRL) has been based in Aiseau-Presles since 2002, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 15,509 € and equity of 234,342 €; its revenue is not published. Its solvency stands at 93.6%, above the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Fasylpharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Anselmo Retail sale of pharmaceutical products Antwerp · balance sheet 249,318 €
- Pharmacie Michèle BRULIAU Retail sale of pharmaceutical products Bastogne · balance sheet 249,253 €
- Lolophar Retail sale of pharmaceutical products Ghent · balance sheet 248,113 €
- Pharma Daive Retail sale of pharmaceutical products Péruwelz · balance sheet 247,671 €
- Apoteek Bellekens Retail sale of pharmaceutical products Antwerp · balance sheet 247,504 €
- Schaffen Pharma Retail sale of pharmaceutical products Diest · balance sheet 246,323 €
- Odepharma Retail sale of pharmaceutical products Koksijde · balance sheet 255,295 €
- Medphar Retail sale of pharmaceutical products Schaerbeek · balance sheet 255,858 €
Frequently asked questions about Fasylpharma
What is the revenue of Fasylpharma?
Fasylpharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Fasylpharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0478056184 for Fasylpharma, if the company is VAT-registered. Its company number (CBE) is 0478.056.184.
Where is the registered office of Fasylpharma?
According to the CBE register, the registered office of Fasylpharma is in 6250 Aiseau-Presles.
What is the equity of Fasylpharma?
At the close of the 2025 financial year, the equity of Fasylpharma amounts to 234,342 €, a solvency of 93.6% of total assets.
Who manages Fasylpharma?
The register lists 2 active mandates at Fasylpharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Fasylpharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →